

## 2022年 英文論文

1. Ishizuka K, Hoshino T, Toi S, Mizuno T, Hosoya M, Saito M, Sato Y, Yagita Y, Todo K, Sakaguchi M, Ohashi T, Maruyama K, Hino S, Honma Y, Doijiri R, Yamagami H, Iguchi Y, Hirano T, Kimura K, Kitazono T, Kitagawa K. Remote ischemic conditioning for acute ischemic stroke part 2: Study protocol for a randomized controlled trial. *Front Neurol.* 2022 Aug 8;13:946431. doi: 10.3389
2. Hoshino T, Mizuno T, Ishizuka K, Takahashi S, Arai S, Toi S, Kitagawa K. Triglyceride-glucose index as a prognostic marker after ischemic stroke or transient ischemic attack: a prospective observational study. *Cardiovasc Diabetol.* 2022 Nov 30;21(1):264. doi: 10.1186/s12933-022-01695-2
3. Mizuno T, Hoshino T, Ishizuka K, Toi S, Takahashi S, Wako S, Arai S, Kitagawa K. Hyperhomocysteinemia Increases Vascular Risk in Stroke Patients with Chronic Kidney Disease. *J Atheroscler Thromb.* 2022 Nov 26. doi: 10.5551/jat.63849.
4. Ishizuka K, Saito M, Shibata N, Kitagawa K. Cytoskeletal protein breakdown and serum albumin extravasation in MRI DWI-T2WI mismatch area in acute murine cerebral ischemia. *Neurosci Res.* 2022 Nov 12:S0168-0102(22)00274-7. doi: 10.1016
5. Saito M, Hoshino T, Ishizuka K, Iwasaki S, Toi S, Shibata N, Kitagawa K. Remote Ischemic Conditioning Enhances Collateral Circulation Through Leptomeningeal Anastomosis and Diminishes Early Ischemic Lesions and Infarct Volume in Middle Cerebral Artery Occlusion. *Transl Stroke Res.* 2022 Nov 28. doi: 10.1007/s12975-022-01108-2.
6. Wako S, Ikeguchi R, Toda K, Kobayashi M, Miyata R, Kuramochi H, Ichihara A, Shimizu Y, Kitagawa K. Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: A case report. *J Neuroimmunol.* 2022 Dec 5;374:578010. doi: 10.1016
7. Negishi N, Ikeguchi R, So H, Kobayashi M, Nitta M, Masui K, Nakamichi K, Takahashi K, Ishida H, Kawamata T, Shibata N, Shimizu Y, Kitagawa K. Successful treatment of progressive multifocal leukoencephalopathy that developed 21 years after renal transplantation: A case report. *Neuroimmunology Reports.* 2022 Jul. 2; 100113. doi: 10.1016/j.nerep.2022.100113
8. Oshima R, Ikeguchi R, Wako S, Mizuno T, Abe K, Nitta M, Muragaki Y, Kawamata T, Masui K, Yamamoto T, Shibata N, Shimizu Y, Kitagawa K. IgG4-related brain pseudotumor mimicking CNS lymphoma. A case report. *Neuropathology.* 2022

Dec;42(6):526-533. doi: 10.1111

9. Shirai Y, Toi S, Adachi U, Tsutsumi Y, Kitagawa K. Cilostazol improves endothelial function in patients with ischemic stroke: A randomized controlled single-center study with flow-mediated dilation technique. *J Neurol Sci.* 2022 Aug 15;439:120318. doi: 10.1016/j.jns.2022.120318.
10. Takahashi S, Ishizuka K, Hoshino T, Mizuno T, Nishimura A, Toi S, Kitagawa K. Long-Term Outcome in Patients With Acute Ischemic Stroke and Heart Failure. *Circ J.* 2022 Apr 19. doi: 10.1253/circj.CJ-21-0937.
11. Kitagawa K. Blood pressure management for secondary stroke prevention. *Hypertens Res.* 2022 Jun;45(6):936-943.
12. Hoshino T, Mizuno T, Nishimura A, Ishizuka K, Toi S, Takahashi S, Wako S, Kitagawa K. Reclassification and risk stratification of embolic stroke of undetermined source by ASCOD phenotyping. *Int J Stroke.* 2022 May 11:17474930221096953. doi: 10.1177/17474930221096953.
13. Seki M, Yoshizawa H, Hosoya M, Kitagawa K. Neuropsychological Profile of Early Cognitive Impairment in Cerebral Small Vessel Disease. *Cerebrovasc Dis.* 2022;51(5):600-607.
14. Takeda T, Iijima M, Seki M, Higuchi E, Shimizu Y, Shibata N, Kitagawa K. Prolonged central motor conduction time and pyramidal tract degeneration in amyotrophic lateral sclerosis. *Clin Neuropathol.* 2022 Jul-Aug;41(4):157-161.
15. Hoshino T, Ishizuka K, Toi S, Mizuno T, Nishimura A, Wako S, Takahashi S, Kitagawa K. Prognostic Role of Hypertriglyceridemia in Patients With Stroke of Atherothrombotic Origin. *Neurology.* 2022 Apr 19;98(16):e1660-e1669.
16. Kitagawa K, Arima H, Yamamoto Y, Ueda S, Rakugi H, Kohro T, Yonemoto K, Matsumoto M, Saruta T, Shimada K; Recurrent Stroke Prevention Clinical Outcome (RESPECT) Study Group. Intensive or standard blood pressure control in patients with a history of ischemic stroke: RESPECT post hoc analysis. *Hypertens Res.* 2022 Apr;45(4):591-601.
17. Mizuno T, Hoshino T, Ishizuka K, Toi S, Nishimura A, Takahashi S, Wako S, Kitagawa K. Characteristics and Prognosis of Stroke in Living Donor Renal Transplant Recipients. *J Atheroscler Thromb.* 2022 Sep 1;29(9):1393-1408.
18. Hoshino T, Ishizuka K, Toi S, Mizuno T, Nishimura A, Takahashi S, Wako S, Kitagawa K. Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack. *Stroke.* 2022 Jan;53(1):79-86.
19. Hoshino T, Ishizuka K, Toi S, Seki M, Kitagawa K. Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery

- Diseases and 3-Month Laboratory Outcomes. *J Atheroscler Thromb.* 2022 Jul 1;29(7):1020-1030.
- 20. Ishizuka K, Toi S, Hoshino T, Higuchi E, Kitagawa K. Localization of Infratentorial Lesion could Predict Patent Foramen Ovale as an Etiology in Embolic Stroke of Undetermined Source. *J Atheroscler Thromb.* 2022 May 1;29(5):785-793.
  - 21. Toi S, Shirai Y, Ishizuka K, Hosoya M, Seki M, Higuchi E, Hoshino T, Kitagawa K. Recurrent Stroke Incidence and Etiology in Patients with Embolic Stroke of Undetermined Source and Other Stroke Subtypes. *J Atheroscler Thromb.* 2022 Mar 1;29(3):393-402.
  - 22. Kobayashi M, Takeuchi M, Suzuki M, Kitagawa K. Demyelinating neuropathy requires differential diagnosis with vasculitic neuropathy in rheumatoid arthritis: Significance of sural nerve electrophysiology findings. *Clin Exp Neuroimmunol* 13;3: 182-189
  - 23. Shimizu Y. Monoclonal antibody treatment for multiple sclerosis and Neuromyelitis optica spectrum disorder: An update. *Clinical and Experimental Neuroimmunology* 2022;13 (3): 131-132.
  - 24. Toyoda K, Omae K, Hoshino H, Uchiyama S, Kimura K, Miwa K, Minematsu K, Yamaguchi K, Suda Y, Toru S, Kitagawa K, Ihara M, Koga M, Yamaguchi T; CSPS.com Trial Investigators. Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis. *Neurology.* 2022 Mar 8;98(10):e983-e992.
  - 25. Uchiyama S, Toyoda K, Okamura S, Omae K, Hoshino H, Kimura K, Kitagawa K, Minematsu K, Yamaguchi T. Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. *Int J Stroke.* 2022 Jul 21:17474930221112343. doi: 10.1177
  - 26. Baba T, Takeda A, Murakami A, Koga T, Isomura T, Mori E, Hisanaga K, Ugawa Y, Hattori N, Murata M, Hasegawa K, Sobue G, Ito H, Yabe I, Yamamoto T, Iijima M, et al. Effect of donepezil for dementia prevention in Parkinson's disease with severe hyposmia (The DASH-PD study): A randomized long-term placebo-controlled trial. *EClinicalMedicine.* 2022 Jul 14;51:101571.doi:10.1016/j.eclinm. 2022.101571.